STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CorMedix to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CorMedix (NASDAQ:CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening conditions, announced its participation in two major healthcare investor conferences in September 2025.

The company's senior management will present at the Cantor Global Healthcare Conference on September 5 at 8:35am ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 at 10:45am ET. Both presentations will be in a fireside chat format with webcasts available.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.

Cantor Global Healthcare Conference

Date:September 5, 2025
Time:8:35am Eastern
Format:Fireside Chat
Webcast:Link to webcast
  

Morgan Stanley 23rd Annual Global Healthcare Conference

Date:September 10, 2025
Time:10:45am Eastern
Format:Fireside Chat
Webcast:Link to webcast
  

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix commenced clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


FAQ

When is CorMedix (CRMD) presenting at the Cantor Global Healthcare Conference 2025?

CorMedix will present at the Cantor Global Healthcare Conference on September 5, 2025 at 8:35am Eastern in a fireside chat format.

What time is CorMedix's presentation at the Morgan Stanley Healthcare Conference 2025?

CorMedix will present at the Morgan Stanley Global Healthcare Conference on September 10, 2025 at 10:45am Eastern in a fireside chat format.

How can investors access CorMedix's (CRMD) conference presentations in September 2025?

Investors can access both presentations via webcasts that will be available for the Cantor and Morgan Stanley healthcare conferences.

Which investor conferences is CorMedix (CRMD) attending in September 2025?

CorMedix is attending two conferences: the Cantor Global Healthcare Conference on September 5 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025.
Cormedix

NASDAQ:CRMD

CRMD Rankings

CRMD Latest News

CRMD Latest SEC Filings

CRMD Stock Data

760.31M
73.24M
7.56%
46.8%
15.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERKELEY HEIGHTS